In-house discovered and In-licensed projects（As of May 13, 2026）
| Development Code | Planned Indication | Development Stage | Remarks |
|---|---|---|---|
| KAR | Head lice | Phase Ⅲ | ・In-licensed from Arbor Pharmaceuticals, LLC.(Currently, Azurity Pharmaceuticals） ・Product name in the US: Sklice ・Announced the topline data from PⅢ trial in Japan |
| KP-001 | Refractory vascular malformations | Phase Ⅲ | ・In-house discovered product |
| KC-8025 | Primary biliary cholangitis | Phase Ⅲ | ・In-licensed from CymaBay Therapeutics, Inc.(Currently, Gilead Sciences, Inc.) ・Product name in US,UK,CA: Livdelzi ・Product name in EU,CA: Lyvdelzi |
| ESK-001 | Plaque psoriasis | Phase Ⅲ | ・In-licensed from Alumis Inc. ・Under global Phase Ⅲ (incl. Japan) |
| Generalized pustular psoriasis ／Erythrodermic psoriasis |
Phase Ⅲ | - | |
| Navenibart | Hereditary angioedema | Phase Ⅲ | ・In-licensed from Astria Therapeutics, Inc. ・Under global Phase Ⅲ (incl. Japan) |
| KP-483 | Solid tumors (immuno-oncology) |
Phase Ⅰ | In-house discovered product |
| KP-910 | Peripheral neuropathic pain | Phase Ⅰ | In-house discovered product |
| KP-001(USA) | Refractory vascular malformations | Phase Ⅲ | In-house discovered product Clinical trial countries:US, CA, Taiwan, Korea |
Note:Kaken will advance KP-723, an oral STAT6 inhibitor, to the completion of PⅠ trials,
which had entered into a license agreement with J&J.
Note: Development of Tildacerfont, a treatment for congenital adrenal hyperplasia, has been discontinued.
Other（As of May 13, 2026）
| Development Code | Planned Indication | Development Stage | Remarks |
|---|---|---|---|
| gMSC1 | Knee osteoarthritis with a focal defect | Preparing for Phase Ⅲ | ・Allogenic synovial mesenchymal stem cell-derived three-dimensional artificial tissue |
| NM-26 | Atopic dermatitis | Phase Ⅱ | ・Clinical trial underway by J&J after IP transfer ・Option rights to negotiate a sales partnership agreement in Japan ・・PⅡb trial discontinued, as announced by J&J (December 26, 2025) |
Note:The medical device “Silk-Elastin Wound Healing Sheet”, for which a marketing authorization application had been submitted by the licensor, Sanyo Chemical Industries, Ltd., was approved on April 21, 2025.
Note:The product "Ekterly® Tablet 300mg (sebetralstat)", for which KalVista Pharmaceuticals, Inc., obtained marketing authorization,was launched on March 18, 2026.
Status of Out-Licensed Products Overseas
（As of May 13, 2026）
| Generic name (domestic sales name) |
Planned Indication | Development Stage | Out-licensed(Developing country) |
|---|---|---|---|
| Efinaconazole (Clenafin) |
Onychomycosis | Phase Ⅲ | AIM(China) |